Hormonal
GLP-1 RAs show potential to slow the progression of neurodegenerative diseases, including Alzheimer's and Parkinson's, by reducing neuroinflammation and potentially acting as neuroprotective agents.
Research suggests GLP-1 medications may help protect against Alzheimer's and Parkinson's disease by reducing brain inflammation. While not yet a standard treatment for these conditions, ongoing clinical trials are investigating their use. If you have risk factors for cognitive decline, discussing these emerging benefits with your doctor may be relevant, especially if you are already using GLP-1s for diabetes or weight management.
Preclinical data have indicated a neuroprotective role for GLP- 1, and current evidence points towards reduced inflammation as the common denominator for the benefits in Alzheimer's disease and other neurological disorders... GLP- 1 RAs are being repurposed as a potential intervention to address the unmet medical need in Alzheimer's disease.
Why this rating
Based on preclinical studies, post-hoc analyses, and ongoing phase 3 trials; not yet definitive large-scale RCTs for all indications.
Source
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
Frederik Flindt Kreiner et al. · Aging Cell · 2023
DOI 10.1111/acel.13818
More from this paper
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) by approximately 14% in patients with type 2 diabetes, independent of glucose-lowering effects.Strong
- GLP-1 RAs promote significant weight loss (up to 18-21% in clinical trials) by acting on central brain regions to modify food preferences, reduce appetite, and increase satiety.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →